Abstract
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review. (Blood. 2013;122(24):3892-3898).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3892-3898 |
| Number of pages | 7 |
| Journal | Blood |
| Volume | 122 |
| Issue number | 24 |
| DOIs | |
| State | Published - Dec 5 2013 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology